{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"3.2","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Summarized for each cohort using the Kaplan-Meier method, from the date of start of treatment to the date of documented progression (based on IMWG criteria) or death due to any cause, assessed every 4 weeks","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nTrametinib: Given PO\n\nUprosertib: Given PO","id":"OG000","title":"Treatment (Trametinib, Akt Inhibitor GSK2141795)"}],"paramType":"MEDIAN","populationDescription":"Note: 25 patients enrolled, however, one patient unevaluable was not included in analysis","reportingStatus":"POSTED","timeFrame":"Time from the date of start of treatment to the date of documented progression (based on IMWG criteria) or death, whichever occurs first, due to any cause, assessed every 4 weeks, an average of 9 months.","title":"PFS","type":"SECONDARY","unitOfMeasure":"months"}